Not Losing Weight on Retatrutide: Causes and Next Steps

Not losing weight on retatrutide can be disheartening, particularly when expectations are high for this investigational triple receptor agonist. Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors to reduce appetite and increase energy expenditure, and early Phase 2 trial data are promising. However, weight loss is rarely straightforward, and a range of medical, lifestyle, and treatment-related factors can slow or stall progress. This article explores the most common reasons why retatrutide may not be working as expected, and outlines practical, evidence-based steps you can take in partnership with your healthcare team.

Why You May Not Be Losing Weight on Retatrutide

Weight loss on retatrutide may stall due to metabolic adaptations, dose escalation still being in progress, or the body's complex response to caloric restriction and hormonal changes. Retatrutide is not yet MHRA or EMA licensed, and UK access is limited to approved clinical trials.

Retatrutide is an investigational triple receptor agonist currently being evaluated in clinical trials for weight management. Early-phase data suggest it may support meaningful weight reduction, though it remains under investigation and no definitive conclusions about its long-term efficacy or safety can yet be drawn.

Weight loss with any pharmacological intervention is rarely linear. Many people experience an initial plateau, a period where the scales do not move despite the medication being active in the body. This can be frustrating, but it does not necessarily mean the treatment is failing. The body undergoes complex metabolic adaptations in response to caloric restriction and hormonal changes, which can temporarily stall progress.

Retatrutide does not currently hold a licence from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK, nor has it received authorisation from the European Medicines Agency (EMA). This can be verified via the MHRA's Find a Medicine search and the EMA's Union Product Database. In the UK, access to retatrutide is generally limited to approved clinical trials. If you believe you are obtaining retatrutide outside of a formal clinical trial, for example from an unregulated or overseas source, please stop and speak to your GP immediately, as the safety and quality of such products cannot be guaranteed. To find legitimate UK trials, the NIHR Be Part of Research register (bepartofresearch.nihr.ac.uk) lists approved studies.

If you are participating in an approved clinical trial and are not seeing expected results, your trial team or clinical investigator should be your first point of contact. Understanding the reasons behind a lack of progress is the first step towards addressing them effectively.

How Retatrutide Works and What to Expect

Retatrutide activates GLP-1, GIP, and glucagon receptors to reduce appetite, enhance insulin secretion, and increase energy expenditure. Phase 2 data showed mean weight reductions of approximately 17 to 24% over 48 weeks, though larger Phase 3 trials are ongoing.

Retatrutide works by simultaneously activating three key hormone receptors involved in appetite regulation and energy metabolism:

• GLP-1 (glucagon-like peptide-1) receptors — reducing appetite and slowing gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) receptors — thought to enhance insulin secretion and potentially support fat metabolism, though the precise contribution in humans is still being investigated

• Glucagon receptors — hypothesised to increase energy expenditure and promote fat breakdown in the liver, based on preclinical and early clinical data

This triple mechanism of action is intended to produce substantial weight loss. Whether it produces greater weight loss than single or dual receptor agonists has not yet been established in head-to-head clinical trials. In a Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving higher doses of retatrutide achieved mean weight reductions of approximately 17 to 24% of body weight over 48 weeks. These findings are promising, though the drug remains under investigation and larger Phase 3 trials are ongoing.

Meaningful weight loss typically takes time to manifest. During the dose escalation period, which is used to minimise gastrointestinal side effects such as nausea, vomiting, and diarrhoea, the full therapeutic dose may not yet be reached. Dose escalation schedules vary by trial protocol and should not be assumed to follow a standard regimen. Patients should therefore not expect dramatic results immediately.

As with other incretin-based therapies, there are potential class-related risks to be aware of, including gallbladder disease and, rarely, pancreatitis.^[21][22] If you experience severe or persistent abdominal pain (particularly pain radiating to the back), are unable to keep fluids down, or show signs of dehydration, contact NHS 111 or go to your nearest A&E for prompt clinical assessment. Call 999 only if you believe your situation is immediately life-threatening.

If you have type 2 diabetes and are taking insulin or a sulphonylurea alongside retatrutide, there may be an increased risk of hypoglycaemia. Discuss this with your prescriber or trial team before starting treatment, so that your diabetes medicines can be reviewed and appropriate monitoring arranged.

If you experience any suspected side effects from a medicine you are taking outside a clinical trial, report them via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk). If you are enrolled in a clinical trial, report adverse events to your trial team as required by your trial protocol; your trial team can advise on any additional reporting routes.

Medical Reasons That Can Slow Weight Loss Progress

Hypothyroidism, PCOS, type 2 diabetes, Cushing's syndrome, and certain medicines including antipsychotics and corticosteroids can significantly impair weight loss even when using an investigational agent such as retatrutide.

Several underlying medical conditions can impair weight loss, even when an investigational medicine such as retatrutide is being used. It is important that these are identified and managed appropriately, as they may significantly reduce the medication's effectiveness.

Common medical factors include:

• Hypothyroidism — an underactive thyroid reduces metabolic rate and can make weight loss considerably more difficult. In line with NICE NG145 (Thyroid disease: assessment and management), thyroid function testing (TSH, and free T4 if indicated) is appropriate when clinical features suggest thyroid dysfunction, such as fatigue, cold intolerance, constipation, or unexplained weight gain, rather than as a routine screen for all patients struggling to lose weight.^[1]

• Polycystic ovary syndrome (PCOS) — associated with insulin resistance and hormonal imbalances that can hinder fat loss, particularly in women of reproductive age. NICE CKS guidance on PCOS provides further detail on assessment and management.

• Type 2 diabetes — insulin resistance and certain diabetes medicines (such as sulphonylureas or insulin itself) can counteract weight loss efforts, as noted in NICE NG28 (Type 2 diabetes in adults: management).

• Cushing's syndrome — excess cortisol production promotes fat accumulation, particularly around the abdomen. If clinical features suggest Cushing's syndrome (such as central weight gain, easy bruising, stretch marks, or proximal muscle weakness), referral to an endocrinologist is advisable.

• Depression and other mental health conditions — these can affect motivation, eating behaviours, and sleep, all of which influence body weight.

Certain medicines are also known to cause weight gain or impede weight loss. According to the BNF and NICE guidance, these include some antidepressants (particularly mirtazapine and amitriptyline), antipsychotics, corticosteroids, insulin, sulphonylureas, and some beta-blockers. Weight effects can vary between individual agents within a class and between patients. If you are taking any of these medicines, discuss with your GP or prescriber whether alternatives exist. Do not stop or change any prescribed medicine without first seeking advice from your prescriber. Addressing these underlying factors is essential before concluding that retatrutide is ineffective.

Lifestyle Factors That May Affect Your Results

High intake of ultra-processed foods, insufficient physical activity, poor sleep, chronic stress, and alcohol consumption can all counteract retatrutide's appetite-suppressing effects and reduce overall weight loss.

Even with an investigational medicine such as retatrutide, lifestyle factors remain critically important determinants of weight loss success. Medication is most effective when used as part of a comprehensive approach that includes dietary modification, physical activity, and behavioural support.

Key lifestyle considerations include:

• Dietary intake — retatrutide reduces appetite, but it does not eliminate the impact of calorie-dense foods. Consuming high amounts of ultra-processed foods, sugary drinks, or alcohol can offset the caloric deficit the medication helps to create. The NHS Eatwell Guide (available at nhs.uk) provides practical, evidence-based advice on a balanced dietary pattern, including plenty of vegetables, lean protein, wholegrains, and healthy fats.

• Physical activity — regular movement supports weight loss and helps preserve lean muscle mass. The UK Chief Medical Officers' Physical Activity Guidelines recommend that adults aim for at least 150 minutes of moderate-intensity aerobic activity per week, alongside muscle-strengthening activities on at least 2 days per week.^[14] Both aerobic exercise and resistance training contribute to overall energy expenditure and metabolic health.

• Sleep quality — poor sleep is strongly associated with increased hunger hormones (ghrelin) and reduced satiety signals (leptin), which can undermine appetite suppression from the medication.

• Stress management — chronic stress elevates cortisol levels, which promotes fat storage and can trigger emotional eating behaviours.

• Alcohol consumption — alcohol is calorie-dense and can stimulate appetite, counteracting appetite suppression. The UK Chief Medical Officers' low-risk drinking guidelines advise keeping alcohol consumption to no more than 14 units per week, spread across three or more days, with several alcohol-free days each week.

Honest self-reflection about these factors, ideally with the support of a dietitian or health coach, can reveal modifiable behaviours that, once addressed, may reinvigorate weight loss progress.

When to Speak to Your Doctor or Prescriber

Seek advice from your trial team or prescriber if you have had no meaningful weight loss on a stable dose, experience persistent side effects, or develop new symptoms suggesting an underlying condition. Contact NHS 111 or go to A&E for severe abdominal pain or signs of dehydration.

Knowing when to seek professional guidance is an important aspect of safe and effective weight management. Because retatrutide is investigational, any decisions about continuing, adjusting, or stopping treatment should be made in close collaboration with your trial team or prescriber, in accordance with your trial protocol and individual clinical circumstances, not based on a fixed timeframe or weight loss threshold.

You should seek advice from your trial team or prescriber if:

• You have been on a stable dose for a sustained period with no meaningful weight loss, as defined by your trial protocol or clinical team

• You are experiencing persistent side effects such as ongoing nausea, vomiting, abdominal discomfort, or changes in bowel habits that are affecting your quality of life or nutritional intake

• You notice unexplained weight gain despite adherence to the treatment programme

• You develop new symptoms that may suggest an underlying medical condition, such as fatigue, cold intolerance, irregular periods, or mood changes

• You are struggling with adherence due to side effects or other concerns, as your prescriber may be able to adjust the dose or offer additional support

If you are enrolled in a clinical trial, report any side effects or adverse events to your trial team promptly, as required by your trial protocol.

Seek urgent medical attention by contacting NHS 111 or going to A&E if you experience:

• Severe or persistent abdominal pain, especially if it radiates to the back (which may indicate pancreatitis or gallbladder disease)

• Inability to keep fluids down, or signs of dehydration (such as dizziness, dark urine, or feeling faint)

Call 999 if you believe your situation is immediately life-threatening.

It is also important to attend all scheduled follow-up appointments as part of your treatment programme. These reviews allow your clinical team to monitor progress, assess tolerability, and make evidence-informed adjustments. Do not discontinue retatrutide without medical advice, as abrupt cessation may affect your overall management plan.

Next Steps If Retatrutide Is Not Working for You

If retatrutide is not producing adequate weight loss, options include dose optimisation under supervision, referral to NHS Tier 3 or Tier 4 weight management services, or switching to a NICE-approved alternative such as semaglutide 2.4 mg or tirzepatide.

If, after a thorough review of medical, lifestyle, and adherence factors, retatrutide still does not appear to be producing adequate weight loss, there are several constructive next steps to consider in partnership with your healthcare team.

Firstly, your prescriber or trial team may consider dose optimisation. Retatrutide is administered in escalating doses according to trial protocol, and some individuals may require higher doses to achieve a meaningful therapeutic response. This should only be done under medical supervision, with careful monitoring for side effects.

Secondly, a multidisciplinary review may be beneficial. This could involve input from an endocrinologist, dietitian, psychologist, or specialist obesity service. In the UK, NHS Tier 3 weight management services offer structured, multi-component programmes for individuals with complex obesity-related needs, typically accessed via GP referral. For those who meet criteria, Tier 4 services provide access to specialist and surgical pathways, in line with the NHS England Adult Severe and Complex Obesity (Tier 4) Service Specification. Availability may vary depending on local Integrated Care Board commissioning arrangements, service capacity, and individual eligibility. Current overarching guidance on obesity management is provided by NICE NG246 (Obesity: identification, assessment and management, 2024), which supersedes much of the earlier CG189.

Thirdly, if retatrutide is genuinely not effective for you, your clinician may discuss alternative pharmacological options. In the UK, NICE-approved treatments for weight management currently include orlistat, semaglutide 2.4 mg (Wegovy; NICE TA875), and tirzepatide (Mounjaro; NICE TA1026) for eligible patients. Each works through different mechanisms and may suit different individuals. Eligibility criteria and commissioning arrangements vary, so discuss with your GP or specialist.

Finally, for those with severe obesity who have not responded to medical management, bariatric surgery may be an option and should be discussed with a specialist. Eligibility thresholds and criteria are set out in NICE NG246 and the NHS England Tier 4 service specification; lower BMI thresholds for assessing health risk in some ethnic groups are described in NICE PH46, though surgical eligibility criteria should be confirmed with your clinical team. Whatever the next step, the goal is to find a safe, sustainable, and personalised approach to weight management that supports your long-term health.

Frequently Asked Questions